Skip to main content

Blackman Samuel C.'s Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Nov 19, 2024

Accession no.
0001415889-24-027234
Filed
Nov 19, 2024
Trade date
Nov 15-18, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $29.1K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Blackman Samuel C.CIK 0001863676Officer (HEAD OF R&D)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 15, 2024Common StockMOption exerciseAcquired+1,187––1,058,722Direct
Nov 15, 2024Common StockMOption exerciseAcquired+1,437––1,060,159Direct
Nov 15, 2024Common StockMOption exerciseAcquired+6,062––1,066,221Direct
Nov 18, 2024Common StockSSaleDisposed−2,206$13.21−$29,141.261,064,015Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 15, 2024Common StockMOption exerciseDisposed−1,187$0.00$04,756Direct
Nov 15, 2024Common StockMOption exerciseDisposed−1,437$0.00$011,504Direct
Nov 15, 2024Common StockMOption exerciseDisposed−6,062$0.00$072,752Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)